- Conditions
- Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
- Interventions
- Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF), Autologous transplant
- Radiation · Drug · Procedure
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 564
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin
- Interventions
- Carmustine, Etoposide phosphate, Cytarabine, Melphalan HCl (propylene glycol-free)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- B-Cell Lymphoma Originating in the CNS
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Fatigue Syndrome
- Interventions
- Nutraceutical supplements, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 25 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy, Young Adults
- Interventions
- RLIC, Sham conditioning, Muscle strength training, Driving training, Balance training
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Musculoskeletal Pain, Neck Pain
- Interventions
- Pain Inducing Massage, Light Touch Massage, Coldpressor
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
- Interventions
- Active Remote Ischemic Conditioning, Sham Remote Ischemic Conditioning, Isometric hand exercise
- Other
- Lead sponsor
- Bronx VA Medical Center
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
- Interventions
- Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma, Bladder Cancer
- Interventions
- Aldesleukin, Fludarabine, Cyclophosphamide, Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stroke
- Interventions
- Real Ischemic Conditioning, Sham Ischemic Conditioning
- Device
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Contrast-induced Acute Kidney Injury
- Interventions
- RIPC, Sham-RIPC
- Device
- Lead sponsor
- Oladipupo Olafiranye, MD, MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Stroke
- Interventions
- Ischemic Conditioning, Antioxidant Supplement
- Device · Dietary Supplement
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Stem Cell Transplantation
- Interventions
- Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Sirolimus, Teclistamab, Talquetamb
- Drug · Biological
- Lead sponsor
- Christopher Strouse
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Low Back Pain
- Interventions
- Physical therapy
- Other
- Lead sponsor
- Brooke Army Medical Center
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
- Interventions
- Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
- Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 2 Months to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sickling Disorder Due to Hemoglobin S
- Interventions
- 131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging
- Drug · Radiation · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- Sirolimus, Methotrexate, Tacrolimus, Cyclosporine, MMF
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
- Conditions
- Leukemia, Lymphoma, Myeloma
- Interventions
- Busulfan, Fludarabine, Campath, Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Melphalan, Autologous Stem Cell Transplant, Fludarabine, Allogeneic Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- pharmacological study, tacrolimus, sirolimus, anti-thymocyte globulin, fludarabine phosphate, busulfan, bortezomib, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
- Other · Drug · Biological + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Recurrent Plasma Cell Myeloma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Daratumumab, Fludarabine, Melphalan, Mycophenolate Mofetil, Tacrolimus
- Procedure · Drug · Biological
- Lead sponsor
- Srinivas Devarakonda
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cardiomyopathies, Heart Rate, Conditioning
- Interventions
- novel atrial pacing approach, sham pacing approach
- Other
- Lead sponsor
- Denise Hodgson-Zingman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Metabolic Disorders
- Interventions
- ProHema-CB Transplant
- Biological
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Durham, North Carolina